GLIA Integrated Healthcare Offers a Gentler, Non-Invasive Approach to Cancer Care, ET HealthWorld

0

Bengaluru: Business Wire India Cancer. The word itself evokes fear and endless struggle with treatments. But what if there was a treatment that was gentler and focused on stopping the growth rather than an all-out war on the disease? Glia Integrated Healthcare has introduced Cytotron therapy, that claims to be a new ray of hope for cancer patients seeking a gentler, non-invasive approach to Cancer care.

In the relentless battle against cancer, the quest for more effective and less invasive treatments has led to significant scientific breakthroughs. Among the most promising innovations in this domain is Cytotron therapy, a non-invasive technology that has opened new frontiers in cancer care.

This groundbreaking approach, leveraging Rotational Field Quantum Magnetic Resonance (RFQMR) to produce modulated Fast Radio Bursts (FRB), the therapeutic signal to regulate the behavior of proteins in the cancer cells, offers a beacon of hope for those navigating the challenging journey of cancer treatment.

THE ADVENT OF CYTOTRON THERAPY: A PARADIGM SHIFT Cytotron therapy emerges as a revolutionary approach, marking a paradigm shift from traditional cancer treatments. This technology targets cancerous cells directly, aiming to inhibit their growth and reduce metastasis, all while preserving the integrity of surrounding healthy tissues.

In the pursuit of innovative solutions for cancer treatment, Cytotron has emerged as a groundbreaking technology with the potential to reshape the landscape of oncology. The Centre for Devices and Radiological Health (CDRH), United States Food and Drug Administration (US-FDA), recognized the Cytotron as a Breakthrough Device for the treatment of Breast, Pancreas and Liver Cancers, for conducting a clinical trial to establish that it is better than existing standards of care for these indications.

The Breakthrough Device designation allows to Fast-track the path to market authorization for use in the USA. Cytotron is invented in India by Dr. Rajah Vijaya Kumar, Group Chairman of Organization de Scalene, Director and Chief Scientific officer of the Centre for Advanced Research and Development (CARD), Bengaluru India. He holds the world-wide patent for the device. Cytotron’s designation as a Breakthrough Device signifies its transformative impact on Cancer Care.

CYTOTRON THERAPY – REENGINEERING THE BODY’S TUMOR SUPPRESSION MECHANISM Cytotron has evolved using Magnetic Resonance Imaging (MRI) based on intrinsic proton density (PD) measurements of target tissue to manipulate biophysical cellular signaling. Highly complex Fast Radio Bursts (FRB) in the safe radio frequency range, in the presence of controlled, high, instantaneous Magnetic Resonance, is precisely focused on target tissues to alter the Transmembrane potential (TMP) of cells which triggers apoptosis (programmed cell death) and stops growth of solid tumors.

The science behind Cytotron therapy is as fascinating as it is hopeful. Cytotron is intended to non-invasively re-activate the body’s tumor suppression mechanism by targeting high precision and calibrated doses of fast radio bursts (FRB) – non-ionising, non-thermal electromagnetic FRBs at the tumor site.

This triggers the production of new tumor suppressing nucleoproteins, predominantly upregulating p53, which determines and flags that the cell is old enough to die. Metastasis is a major challenge in cancer treatment, as it makes the disease more difficult to manage and reduces the effectiveness of localized therapies such as surgery or radiation.

Depending on which stage of cancer is being treated, Cytotron therapy is intended to stop the cancer cells from spreading (Metastasis) from that stage. If Cytotron therapy is used at an early stage, the cancer gets arrested at that point. Once we stop the tumor from growing and spreading, there are other modalities and standard of care that can manage the disease further.

Cytotron acts on the mitochondrial membrane and interfere with communication between the gene transcription machinery and the protoplasmic glycoproteinic complexes involved in the promotion of cellular mitosis. Based on the outcomes reported in treating malignant lesions, the Cytotron induces such alterations of the TMP in a controlled manner, to modify cellular command and control and alter cellular activity to stabilize and arrest tumor progression.

A NEW HOPE: THE ADVANTAGES OF CYTOTRON THERAPY The introduction of Cytotron therapy into the cancer treatment landscape brings numerous advantages. Its non-invasive nature and without any adverse side effects, stands at the forefront, offering a treatment option with fewer complications and a quicker return to daily life.

Dr. Anjana Nair, Medical Director at Glia Integrated Healthcare, Bengaluru and a leading expert in Cytotron therapy at Glia, highlights the potential benefits, “it’s painless, avoids harsh side effects, non-toxic and can improve a patient’s quality of life.” The potential of Cytotron in the realm of medical science is vast and holds promise for the future of cancer treatment. As research continues and the technology evolves, Cytotron could soon become a pivotal player in the broader landscape of oncology. Here are some key areas where Cytotron could make a lasting impact: 1. Early-Stage Intervention: Cytotron’s precision-guided approach makes it well-suited for early-stage cancer intervention.

Treating cancer at its inception can significantly enhance the chances of successful outcomes. Cytotron’s application in addressing early stage cancer has seen an excellent prognosis. 2. Combination Therapies: Cytotron treatment can potentially be integrated with other existing cancer therapies, creating a comprehensive approach that tackles the disease from multiple angles.

This synergy could lead to enhanced treatment efficacy and better QoL outcomes even in 4th stage or palliative care patients. 3. Expanding Treatment Options: The non-invasive nature of Cytotron makes it an attractive option for patients who may not be suitable candidates for treatments like chemotherapy, etc, due to age, health conditions, or other factors.

This expansion of treatment option ensures that a broader spectrum of patients can benefit from this cutting-edge cancer care. 4. Reduced Healthcare Costs: By minimizing the need for invasive surgeries, long hospital stays, and extensive recovery periods, Cytotron has the potential to contribute to cost-effective cancer care. This not only benefits patients but also alleviates the economic burden on healthcare systems.

While it does not claim to cure all types of cancers, Cytotron therapy presents a new weapon in the fight against certain cancers. Non-solid tumors like Leukemia and Multiple Myeloma cannot be treated with Cytotron. GLIA INTEGRATED HEALTHCARE : INTEGRATING CYTOTRON THERAPY INTO COMPREHENSIVE CANCER CARE As we stand on the brink of a new era in cancer treatment, the integration of Cytotron therapy into comprehensive care plans is gaining momentum. Clinical trials and research are continuously unveiling the efficacy and safety of this therapy, making it a compelling option for patients and healthcare providers alike.

These studies are critical for not only validating the effectiveness of Cytotron therapy but also for exploring how it can be combined with other treatments, such as immunotherapy, to enhance patient outcomes and as adjuvant therapy with radiation or hormone therapy to lower the risk of side effects and the cancer recurrence. Glia Integrated Healthcare, with its focus on innovative solutions, is at the forefront of offering this option to patients.

THE PATH FORWARD Despite the promise of Cytotron therapy, challenges remain in making this therapy widely accessible. Issues such as cost for setting up new centers, cashless insurance coverage, lack of awareness, need for specialized equipment can be barriers to widespread adoption.

However, ongoing research, advocacy, and policy development are key to overcoming these hurdles, ensuring that more patients can benefit from this innovative treatment. “We are committed to making CYTOTRON accessible to as many patients as possible. We are in talks with many hospitals to set-up Cytotron therapy centers across India,” stated Dr. Raghu Pillai, Managing Director of Glia Integrated Healthcare.

“This is a significant step towards redefining cancer care, and we are excited about the positive impact it is having on countless lives.” In embracing the potential of such advancements, it’s crucial for patients, healthcare providers, and the broader community to stay informed and engaged.

(Disclaimer: The above press release comes to you under an arrangement with Business Wire India and takes no editorial responsibility for the same.). PTI PWR PWR

  • Published On May 9, 2024 at 04:35 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


link

Leave a Reply

Your email address will not be published. Required fields are marked *